123 related articles for article (PubMed ID: 27746118)
61. Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.
Michaelis M; Klassert D; Barth S; Suhan T; Breitling R; Mayer B; Hinsch N; Doerr HW; Cinatl J; Cinatl J
Mol Cancer; 2009 Sep; 8():80. PubMed ID: 19788758
[TBL] [Abstract][Full Text] [Related]
62. Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Dragoj M; Milosevic Z; Bankovic J; Tanic N; Pesic M; Stankovic T
Cell Oncol (Dordr); 2017 Feb; 40(1):47-62. PubMed ID: 27822706
[TBL] [Abstract][Full Text] [Related]
63. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
Fortunato A
Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
[TBL] [Abstract][Full Text] [Related]
64. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
65. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.
Mi J; Zhang X; Rabbani ZN; Liu Y; Reddy SK; Su Z; Salahuddin FK; Viles K; Giangrande PH; Dewhirst MW; Sullenger BA; Kontos CD; Clary BM
Mol Ther; 2008 Jan; 16(1):66-73. PubMed ID: 17912235
[TBL] [Abstract][Full Text] [Related]
66. Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes.
Hu Y; Pang E; Lai PB; Squire JA; MacGregor PF; Beheshti B; Albert M; Leung TW; Wong N
Int J Oncol; 2004 Nov; 25(5):1357-64. PubMed ID: 15492826
[TBL] [Abstract][Full Text] [Related]
67. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
68. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.
Barraud L; Merle P; Soma E; Lefrançois L; Guerret S; Chevallier M; Dubernet C; Couvreur P; Trépo C; Vitvitski L
J Hepatol; 2005 May; 42(5):736-43. PubMed ID: 15826724
[TBL] [Abstract][Full Text] [Related]
69. Development of human leukemia U-937 cell sublines resistant to doxorubicin: induction of differentiation and altered sensitivities to topoisomerase-directed drugs.
Pantazis P; Dejesus A; Early J; Rodriguez R; Chatterjee D; Han Z; Wyche J; Giovanella B
Anticancer Res; 1995; 15(5B):1873-81. PubMed ID: 8572572
[TBL] [Abstract][Full Text] [Related]
70. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
71. Intracellular glutathione level and efflux in human melanoma and cervical cancer cells differing in doxorubicin resistance.
Drozd E; Gruber B; Marczewska J; Drozd J; Anuszewska E
Postepy Hig Med Dosw (Online); 2016 Apr; 70():319-28. PubMed ID: 27117108
[TBL] [Abstract][Full Text] [Related]
72. Basic fibroblast growth factor promotes doxorubicin resistance in chondrosarcoma cells by affecting XRCC5 expression.
Hsieh MJ; Huang C; Lin CC; Tang CH; Lin CY; Lee IN; Huang HC; Chen JC
Mol Carcinog; 2020 Mar; 59(3):293-303. PubMed ID: 31916307
[TBL] [Abstract][Full Text] [Related]
73. Resistance-associated signatures in breast cancer.
Györffy B
Recent Results Cancer Res; 2007; 176():37-50. PubMed ID: 17607915
[TBL] [Abstract][Full Text] [Related]
74. The Complex Dynamic of Phase I Drug Metabolism in the Early Stages of Doxorubicin Resistance in Breast Cancer Cells.
Barata IS; Gomes BC; Rodrigues AS; Rueff J; Kranendonk M; Esteves F
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360213
[TBL] [Abstract][Full Text] [Related]
75. Long non-coding RNAs in the doxorubicin resistance of cancer cells.
Ashrafizaveh S; Ashrafizadeh M; Zarrabi A; Husmandi K; Zabolian A; Shahinozzaman M; Aref AR; Hamblin MR; Nabavi N; Crea F; Wang Y; Ahn KS
Cancer Lett; 2021 Jun; 508():104-114. PubMed ID: 33766750
[TBL] [Abstract][Full Text] [Related]
76. Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology.
Han J; Jun Y; Kim SH; Hoang HH; Jung Y; Kim S; Kim J; Austin RH; Lee S; Park S
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14283-14288. PubMed ID: 27911816
[TBL] [Abstract][Full Text] [Related]
77. The different expression of TRPM7 and MagT1 impacts on the proliferation of colon carcinoma cells sensitive or resistant to doxorubicin.
Cazzaniga A; Moscheni C; Trapani V; Wolf FI; Farruggia G; Sargenti A; Iotti S; Maier JA; Castiglioni S
Sci Rep; 2017 Jan; 7():40538. PubMed ID: 28094304
[TBL] [Abstract][Full Text] [Related]
78. Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition.
Bao Y; Lu Y; Wang X; Feng W; Sun X; Guo H; Tang C; Zhang X; Shi Q; Yu H
Cancer Cell Int; 2015; 15():109. PubMed ID: 26581310
[TBL] [Abstract][Full Text] [Related]
79. Genome-wide DNA methylation and RNA-seq analyses identify genes and pathways associated with doxorubicin resistance in a canine diffuse large B-cell lymphoma cell line.
Hsu CH; Tomiyasu H; Liao CH; Lin CS
PLoS One; 2021; 16(5):e0250013. PubMed ID: 33961622
[TBL] [Abstract][Full Text] [Related]
80. A comprehensive review on time-tested anticancer drug doxorubicin.
Sritharan S; Sivalingam N
Life Sci; 2021 Aug; 278():119527. PubMed ID: 33887349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
